WB, IP, IF-F, IF-IC
H M Mk
Endogenous
140-200
Rabbit IgG
#O15439
10257
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Frozen) | 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala1023 of human ABCC4 protein.
Background
ABCC4 is a member of the ATP-binding Cassette (ABC) transporter family. ABC proteins transport various molecules across cellular membranes by utilizing the energy generated from ATP hydrolysis. There are seven subfamilies of ABC proteins: ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White (1). ABCC4 belongs to the MRP subfamily, which is involved in multi-drug resistance, hence it is also named MRP4. ABCC4 is widely expressed in tissues including prostate, kidney proximal tubules, astrocytes and capillary endothelial cells of the brain, platelets, and many cancer cell lines (2-4). ABCC4 mediates efflux transport of a wide variety of endogenous and xenobiotic organic anionic compounds (5). The diversity of substrates determines the biological functions of ABCC4. It regulates cAMP levels in human leukemia cells, thereby controlling the proliferation and differentiation of leukemia cells (6). ABCC4 also enables COX deficient pancreatic cancer cells to obtain exogenous prostaglandins (7). Research studies have shown that ABCC4 expression is elevated in drug resistant cancer cells, which makes it a potential target for cancer therapy (8,9). ABCC4 localizes to both plasma membrane and intracellular membranous structures (10). Investigators have also implicated ABCC4 in the pathogenesis of Kawasaki disease, a childhood genetic disorder characterized by vasculitis (11).
- Nakanishi, T. Cancer Genomics Proteomics 4, 241-54.
- Kool, M. et al. (1997) Cancer Res 57, 3537-47.
- Lee, K. et al. (1998) Cancer Res 58, 2741-7.
- Nies, A.T. et al. (2004) Neuroscience 129, 349-60.
- Giacomini, K.M. et al. (2010) Nat Rev Drug Discov 9, 215-36.
- Copsel, S. et al. (2011) J Biol Chem 286, 6979-88.
- Omura, N. et al. (2010) Mol Cancer Res 8, 821-32.
- Bronger, H. et al. (2005) Cancer Res 65, 11419-28.
- Hagmann, W. et al. (2009) Pancreatology 9, 136-44.
- Rius, M. et al. (2008) J Pharmacol Exp Ther 324, 86-94.
- Khor, C.C. et al. (2011) J Med Genet 48, 467-72.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.